Beginning today, American hospitals can purchase Veklury (remdesivir) directly from the drug’s distributor, the Department of Health and Human Services announced today.

Due to limited supply, the federal government previously allocated and distributed the antiviral drug, authorized for emergency use to treat hospitalized adult and pediatric patients with suspected or laboratory-confirmed COVID-19.

Gilead Sciences, which makes the drug, said it is “now meeting real-time demand for Veklury in the United States and anticipates meeting global demand for Veklury in October, even in the event of potential future surges of COVID-19.”

To ensure stable management of drug supply in the near term, AmerisourceBergen will continue to serve as the sole U.S. distributor through the end of this year and will sell the product directly to hospitals, the company said. It said hospitals “will control the quantity of Veklury that they order, enabling them to have ample, predictable supply of Veklury in advance of any anticipated increase in COVID-19 incidence.”

Related News Articles

Headline
In partnership with the AHA’s Center for Health Innovation and other national health care organizations, the Centers for Disease Control and Prevention today…
Headline
The Food and Drug Administration yesterday released an updated template for developers requesting emergency use authorization for antigen tests for…
Headline
As physician practices reopen and hospitals around the country prepare for a second wave of COVID-19 infections coinciding with cold and flu season, the AHA…
Headline
The AHA today released a new public service announcement emphasizing the importance of wearing a mask to help Americans get back to doing the things they love…
Headline
The Department of Health and Human Services yesterday released initial data on how states and territories plan to use their share of 100 million rapid point-of…
Headline
According to an analysis of COVID-19 hospitalization data from 13 states, released today by the Centers for Disease Control and Prevention, 6% of adults…